HF/Transplantation News

A single burst of antitachycardia pacing before an implantable cardioverter defibrillator shock lowered risk for all-cause shock compared with a standard shock protocol, according to the results of the APPRAISE ATP trial.

A novel lead for use in implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators exceeded the safety and efficacy thresholds in the LEADR trial, researchers reported at Heart Rhythm 2024.

Most childhood cancer survivors are not up to date on guideline-recommended screening for late effects of cancer treatment or second malignancies, according to study results.

A system including a leadless pacemaker and a subcutaneous implantable cardioverter defibrillator that wirelessly communicate with each other was safe in patients at risk for fatal ventricular arrhythmias at 6 months, researchers reported.

For athletes with arrhythmias, the return-to-play decision should be individualized based on appropriate risk assessment and treatment and the shared decision-making process should be used, according to a new expert statement.

Implicity announced it received 510(k) clearance from the FDA for its new AI algorithm to assess risk for future HF events from data gathered from various cardiac implantable electronic devices.

No athlete with a positive test for genetic heart disease but a negligible clinical phenotype had a genetic heart disease-associated death or cardiac event in more than 1,500 person-years of follow-up, researchers reported.

Abbott/Thoratec Corp. announced the recall of its left ventricular assist device implant kit due to complaints of blood leakage or air entering the seal interface between the LVAD inflow cannula and the apical cuff.

Moderate to vigorous aerobic and resistance exercise may improve vascular function among cancer survivors, according to findings presented at American Association for Cancer Research Annual Meeting.

In patients with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor aficamten improved exercise capacity and quality of life compared with placebo, according to the results of the SEQUOIA-HCM trial.